Boston Scientific Goes on a Buying Spree
Just a couple of years ago, the notion that cardiovascular device companies would begin to build broad franchises or platforms would have been unthinkable. Go tell that to Boston Scientific.
You may also be interested in...
Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
EU Business News: PharmaSGP Makes Record Start, BioGaia Heads To Canada, Ardian Takes Nutripure Stake
Round-up of European consumer health business news: Germany's PharmaSGP breaks sales record in Q1 as acquired brands grow; probiotics player BioGaia plans direct distribution in Canada; and private-equity firm Ardian takes a stake in French e-commerce supplements specialist Nutripure.